Open-label Study of TAK-875

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01433419
First received: September 12, 2011
Last updated: March 21, 2013
Last verified: March 2013

September 12, 2011
March 21, 2013
January 2012
December 2012   (final data collection date for primary outcome measure)
Adverse events [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01433419 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Open-label Study of TAK-875
Not Provided

The purpose of this study is to evaluate the safety and efficacy of treatment with TAK-875 in diabetic patients.

Not Provided
Interventional
Phase 3
Intervention Model: Parallel Assignment
Diabetes Mellitus
Drug: TAK-875
  • Experimental: TAK-875 25 mg
    Intervention: Drug: TAK-875
  • Experimental: TAK-875 50 mg
    Intervention: Drug: TAK-875
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
333
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The participant is an outpatient.
  2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

  1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
  2. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.
Both
20 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01433419
TAK-875/OCT-003, U1111-1124-1619, JapicCTI-111605
Not Provided
Takeda
Takeda
Not Provided
Not Provided
Takeda
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP